---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-000695"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:22:34.657842+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech regains Nasdaq compliance, avoiding delisting

## Summary
- Nasdaq staff notified Panel on Jan 6, 2026 that Moleculin regained compliance with Listing Rule 5550(b)(1) (min $2.5M equity).
- Company received delist determination on Nov 20, 2025 and had appealed; hearing now cancelled.
- Company is in compliance with all applicable Nasdaq continued listing standards as of Jan 6, 2026.

## SEC filing metadata
- accession: 0001437749-26-000695
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926000695/0001437749-26-000695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926000695/mbrx20260106_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-000695
- JSON: https://secwatch.observer/filing/0001437749-26-000695.json
- Plain text: https://secwatch.observer/filing/0001437749-26-000695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.